FDA approves Viread for hepatitis B
The FDA has approved Viread (tenofovir disoproxil fumarate, from Gilead) for the treatment of chronic hepatitis B in adults. This approval is based on data from two double-blind clinical trials of >400 subjects that showed a greater percentage of patients on Viread achieved a complete response to treatment compared to those who received Hepsera (adefovir dipivoxil, from Gilead).
Viread, a reverse transcriptase inhibitor, is already approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
For more information call (800) GILEAD-5 or visit www.viread.com.